Related Experiment Video
Updated: Dec 21, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.3K
Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice
A Sahuquillo-Torralba1, B de Unamuno Bustos1, M Rodríguez Serna1
1Servicio de Dermatología, Hospital Universitari i Politècnic La Fe, Valencia, España.
Actas Dermo-Sifiliograficas
|May 20, 2020
Summary
Apremilast (a phosphodiesterase-4 inhibitor) shows effectiveness and safety for palmar-plantar psoriasis. However, it is not recommended for scalp psoriasis, with nearly two-thirds of patients experiencing adverse effects.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Limited data exists on the real-world application of oral apremilast, a phosphodiesterase-4 inhibitor.
- This study evaluates the safety and persistence of apremilast in routine clinical practice for various forms of plaque psoriasis.
Observation:
- A retrospective study included 30 patients with psoriasis treated with apremilast from January 2016 to December 2017.
- Patient groups included palmar-plantar psoriasis (12), scalp psoriasis (8), and other plaque psoriasis locations (10).
Findings:
- Survival analysis indicated a probable treatment persistence of 18.5 months for the 50th percentile of patients.
- Apremilast demonstrated efficacy and safety in treating palmar-plantar and other plaque psoriasis locations.
- The drug was found to be ineffective for scalp psoriasis.
- Adverse effects necessitating treatment discontinuation occurred in approximately 66% of patients.
Implications:
- Apremilast is a viable oral treatment option for specific types of psoriasis, excluding scalp involvement.
- Understanding adverse effect profiles is crucial for managing patients on apremilast therapy.
- Further research may explore strategies to mitigate side effects and improve persistence for scalp psoriasis patients.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
370
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
370
01:20Asthma: Pathogenesis and Management
1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.4K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K
01:30Asthma-IV: Nursing Management
3.6K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.6K